Jagsonpal Pharmaceuticals Limited announced the financial results for Q3 FY23 quarter ended December 31st, 2022 revenues grew by 11.6% to Rs. 60.1 crore. 

 

Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore. 

 

Commenting on the company’s performance, Manish Gupta, Managing Director said, “Our performance in the current quarter continues to reflect the strong brand equity and business model of Jagsonpal in India. Our focus on key brands has resulted in 11.6% growth in sales which should further accelerate going forward. Improved product mix and strong control on costs has resulted in improvements across all key margin ratios."

 

"All our key brands are on a growth track with the Dydrogesterone franchise (Divatrone and ProRetro) leading the way despite hyper-competition in the molecule. The business added Rs. 16 crores of free cash during the quarter with our investable balance now exceeding Rs. 100 crore. This provides us the necessary wherewithal to explore inorganic strategies," commented Gupta. 

 

"Our performance in the last six months is a result of our consistent focus to bring Jagsonpal’s financial performance in line with its peers. We now have a clear roadmap for accelerating growth which should start reflecting in our performance from FY24,” added Gupta. 

 

Jagsonpal Pharmaceuticals Limited is a Delhi-based pharmaceutical company. Founded in 1978, the company has a proven track record of 40+ years of catering to the Indian pharmaceutical market. The company has a robust portfolio of drugs focusing on the gynecology and orthopedic segments. 

 

Over the years, the company has successfully built multiple brands that today hold market-leading positions in respective segments. It has created a niche for itself in these value- accretive segments which resulted in mid-teens' CAGR in revenues over the last four years reaching Rs. 217.6 crore in FY22.